We are committed to being an evidence-based businessClinical Data
Cannabinoid Product Development
CP has recognised the need to associate novel formulations, specific medical conditions and plant science discoveries to drive the creation of meaningful patent estates supported by robust datasets from lab to vial.
The global medical communities and regulatory authorities demand statistically meaningful data to support the prescribing of cannabinoid-based medicines. CP is evolving a publication/IP strategy that will deliver a steady flow of data to position the business as a leading pharmaceutical provider.